Acta obstetricia et gynecologica Scandinavica · 1998
Raised levels of maternal serum secretory acetylcholinesterase may be indicative of fetal neural tube defects in early pregnancy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brennand D M, Jehanli A M, Wood P J, Smith J L
Аннотация
BACKGROUND: To investigate the levels of maternal serum secretory acetylcholinesterase from a sample of pregnancies involving fetal neural tube defects and compare those results with alphafetoprotein levels.
METHODS: Secretory acetylcholinesterase levels were measured using a new Enzyme Capture Immunoassay, in a small blind prospective study. The study group comprised pregnancies covering a gestational age range of 13-24 weeks where 98 had normal fetuses, 21 suffered from neural tube defects, and 15 had other complications.
RESULTS: Maternal serum secretory acetylcholinesterase levels were found to be low and independent of gestational age between 14-20 weeks in a sample of normal pregnancies with normal alphafetoprotein levels. Raised levels of maternal serum secretory acetylcholinesterase were found in 100% of pregnancies involving spina bifida (17/17) and three of four anencephalics compared with raised alphafetoprotein levels found in 88% (15/17), and 100% (4/4) of the same samples. Only seven of 13 maternal serum samples from pregnancies with a normal outcome and none of the four twin pregnancies, all with raised alphafetoprotein levels, had raised secretory acetylcholinesterase levels.
CONCLUSIONS: Raised levels of maternal serum secretory acetylcholinesterase may provide a useful indicator of neural tube defects in early pregnancy.
METHODS: Secretory acetylcholinesterase levels were measured using a new Enzyme Capture Immunoassay, in a small blind prospective study. The study group comprised pregnancies covering a gestational age range of 13-24 weeks where 98 had normal fetuses, 21 suffered from neural tube defects, and 15 had other complications.
RESULTS: Maternal serum secretory acetylcholinesterase levels were found to be low and independent of gestational age between 14-20 weeks in a sample of normal pregnancies with normal alphafetoprotein levels. Raised levels of maternal serum secretory acetylcholinesterase were found in 100% of pregnancies involving spina bifida (17/17) and three of four anencephalics compared with raised alphafetoprotein levels found in 88% (15/17), and 100% (4/4) of the same samples. Only seven of 13 maternal serum samples from pregnancies with a normal outcome and none of the four twin pregnancies, all with raised alphafetoprotein levels, had raised secretory acetylcholinesterase levels.
CONCLUSIONS: Raised levels of maternal serum secretory acetylcholinesterase may provide a useful indicator of neural tube defects in early pregnancy.